Japan Tobacco to buy British rival Gallaher for 2.25 tril. yen

Japan Tobacco to buy British rival Gallaher for 2.25 tril. yen

TOKYO, Japan - Japan Tobacco Inc. President Hiroshi Kimura tells a press conference at a Tokyo hotel on Dec. 15 the world's No. 3 tobacco company has reached a basic agreement to buy smaller rival Gallaher Group Plc of Britain for 2.25 trillion yen (about $19.08 billion). Iit would be the largest-ever corporate acquisition by a Japanese firm. (Kyodo)

  • Product Code
  • ILEA000034667
  • Registered date
  • 2006/12/15 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • Media size
  • 1599 × 2003 pixel
  • Resolution
  • 72 dpi
  • Deployment size
  • 345.23(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos

    BOJ policy-setting meeting

    TOKYO, Japan, Dec. 19 Kyodo - Bank of Japan Governor Kazuo Ueda holds a press conference at the central bank's headquarters in Tokyo on Dec. 19, 2024, after the BOJ kept its key interest rate unchanged at around 0.25 percent during a two-day policy-setting meeting. (Kyodo)
      Unitika to leave textile business

      Unitika to leave textile business

      Unitika Ltd. President Shuji Ueno bows during a press conference in Osaka on Nov. 28, 2024. The company, which started in 1889 as a textiles firm, announced the same day it will pull out of the loss-making side to its business and instead focus on packaging film for food and other polymer products.
        Unitika to leave textile business

        Unitika to leave textile business

        Unitika Ltd. President Shuji Ueno holds a press conference in Osaka on Nov. 28, 2024. The company, which started in 1889 as a textiles firm, announced the same day it will pull out of the loss-making side to its business and instead focus on packaging film for food and other polymer products.
          Unitika to leave textile business

          Unitika to leave textile business

          Unitika Ltd. President Shuji Ueno holds a press conference in Osaka on Nov. 28, 2024. The company, which started in 1889 as a textiles firm, announced the same day it will pull out of the loss-making side to its business and instead focus on packaging film for food and other polymer products.
            Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

            Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

            BAYEUX, FRANCE - OCTOBER 13: A view of Doliprane 1000g boxes placed in front of a computer screen displaying the Sanofi logo, in Bayeux, Calvados, France, on October 13, 2024. Sanofi, the world's fifth-largest pharmaceutical company, is divesting a portion of its business by selling its consumer healthcare division, Opella, which includes around a hundred of its consumer health products, to the American investment fund Clayton, Dubilier and Rice (CDandR) for over 15 billion euros. (Photo by Artur Widak/NurPhoto)
              Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

              Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

              BAYEUX, FRANCE - OCTOBER 13: A view of Doliprane 1000g boxes placed in front of a computer screen displaying the Sanofi logo, in Bayeux, Calvados, France, on October 13, 2024. Sanofi, the world's fifth-largest pharmaceutical company, is divesting a portion of its business by selling its consumer healthcare division, Opella, which includes around a hundred of its consumer health products, to the American investment fund Clayton, Dubilier and Rice (CDandR) for over 15 billion euros. (Photo by Artur Widak/NurPhoto)
                Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

                Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

                BAYEUX, FRANCE - OCTOBER 13: A view of Doliprane 1000g boxes placed in front of a computer screen displaying the Sanofi logo, in Bayeux, Calvados, France, on October 13, 2024. Sanofi, the world's fifth-largest pharmaceutical company, is divesting a portion of its business by selling its consumer healthcare division, Opella, which includes around a hundred of its consumer health products, to the American investment fund Clayton, Dubilier and Rice (CDandR) for over 15 billion euros. (Photo by Artur Widak/NurPhoto)
                  Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

                  Sanofi 15 Billion Sale Of Opella And Doliprane To CDR

                  BAYEUX, FRANCE - OCTOBER 13: A view of Doliprane 1000g boxes placed in front of a computer screen displaying the Sanofi logo, in Bayeux, Calvados, France, on October 13, 2024. Sanofi, the world's fifth-largest pharmaceutical company, is divesting a portion of its business by selling its consumer healthcare division, Opella, which includes around a hundred of its consumer health products, to the American investment fund Clayton, Dubilier and Rice (CDandR) for over 15 billion euros. (Photo by Artur Widak/NurPhoto)
                    India-Bunicess -Tata

                    India-Bunicess -Tata

                    Mr. Chanakya Chaudhary, Vice President of Corporate Service at Tata Steel, and actress Koushani Mukherjee attend the Tata Steel World 25K Kolkata Meet the Press in Kolkata, India, on September 18, 2024. (Photo by Debajyoti Chakraborty/NurPhoto)
                      India-Bunicess -Tata

                      India-Bunicess -Tata

                      Mr. Chanakya Chaudhary, Vice President of Corporate Service at Tata Steel, and actress Koushani Mukherjee attend the Tata Steel World 25K Kolkata Meet the Press in Kolkata, India, on September 18, 2024. (Photo by Debajyoti Chakraborty/NurPhoto)